CD33 and acute myeloid leukemia: The addition of 33-3-19 resulted in the elimination of more than 97% of CFCs from a biphenotypic Philadelphia chromosome-positive B-precursor ALL cell line (BV173) as well as a CD33+ AML M5a cell line (MOLM-13) (Figure 2B and 2C).